Clinical Trial Update: Regulatory Post-Marketing Surveillance Study for TETRAXIM™ [Phase 4]

View source ↗

Summary

Phase 4 post-marketing surveillance study for TETRAXIM. The trial completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• TETRAXIM (Diphtheria, Tetanus, Pertussis, Poliomyelitis, Haemophilus influenzae type b conjugate vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 4 | Status: COMPLETED | Results posted: 2017-01-04